ANDA Submission Wave Continues; Is A Crest Near?
Executive Summary
Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.
You may also be interested in...
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.
Generic Application Quality Showing Signs Of Improvement
US FDA’s monthly refuse-to-receive numbers for ANDAs are down early in FY 2017, suggesting that sponsor have an increased understanding of the agency’s standards.